Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells

BACKGROUND: Due to the frequent dysregulation of the PI3K/AKT/mTOR signaling pathway, mTOR represents a suitable therapeutic target in hepatocellular carcinoma (HCC). However, emerging data from clinical trials of HCC patients indicate that mTOR inhibition by RAD001 (Everolimus) alone has only moder...

Descripción completa

Detalles Bibliográficos
Autores principales: Grabinski, Nicole, Ewald, Florian, Hofmann, Bianca T, Staufer, Katharina, Schumacher, Udo, Nashan, Björn, Jücker, Manfred
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3545733/
https://www.ncbi.nlm.nih.gov/pubmed/23167739
http://dx.doi.org/10.1186/1476-4598-11-85

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3545733/
https://www.ncbi.nlm.nih.gov/pubmed/23167739
http://dx.doi.org/10.1186/1476-4598-11-85

Ejemplares similares